Clinical Trial Update: Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) [Phase 2]

View source ↗

Summary

A Phase 2a trial of VX-407 in participants with autosomal dominant polycystic kidney disease who carry a subset of PKD1 gene variants; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• VX-407

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 2 | Status: RECRUITING